1256497-68-3

Upstream product

• 1256497-66-1 {4-[3-(tert-butyldimethylsilyloxy)propoxy]-2-methoxyphenyl}methanol 
• 1256497-65-0 4-[3-(tert-butyldimethylsilyloxy)propoxy]-2-methoxybenzaldehyde 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 1376514-42-9 tert-butyl {3-[4-(chloromethyl)-3-methoxyphenoxy]propoxy}dimethylsilane 
• 105-45-3 acetoacetic acid methyl ester 
• 89031-84-5 3-(tert-butyldimethylsilyloxy)propyl bromide 

Downstream Products

• 1256497-69-4 2-amino-5-{4-[3-(tert-butyldimethylsilyloxy)propoxy]-2-methoxybenzyl}-6-methylpyrimidin-4-ol 
• 1256497-70-7 2-amino-5-{4-[3-(tert-butyldimethylsilyloxy)propoxy]-2-methoxybenzyl}-6-methylpyrimidin-4-yl 2,4,6-trimethylbenzenesulfonate 
• 1376514-49-6 (3S)-3-[(2-amino-5-{4-[3-(dimethylamino)propoxy]-2-methoxybenzyl}-6-methylpyrimidin-4-yl)amino]hexan-1-ol 
• 1378275-52-5 (S)-3-(2-amino-5-{4-[3-(2-hydroxyethylamino)propoxy]-2-methoxybenzyl}-6-methylpyrimidin-4-ylamino)hexan-1-ol 
• 1376514-46-3 3-{4-[(2-amino-4-{[(3S)-1-(benzyloxy)hexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxyphenoxy}propan-1-ol 
• 1376514-47-4 3-{4-[(2-amino-4-{[(3S)-1-(benzyloxy)hexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxyphenoxy}propyl methanesulfonate 
• 1378275-59-2 (S)-2-{3-[4-({2-amino-4-[1-(benzyloxy)hexan-3-ylamino]-6-methylpyrimidin-5-yl}methyl)-3-methoxyphenoxy]propylamino}ethanol 
• 1378275-60-5 C₃₀H₄₃N₅O₃ 
• 1376514-45-2 N₄-[(3S)-1-(benzyloxy)hexan-3-yl]-5-[4-(3-{[tert-butyl(dimethyl)silyl]oxy}propoxy)-2-methoxybenzyl]-6-methylpyrimidine-2,4-diamine 
• 1378275-63-8 (S)-N₄-[1-(benzyloxy)hexan-3-yl]-5-{2-methoxy-4-[3-(piperazin-1-yl)propoxy]benzyl}-6-methylpyrimidine-2,4-diamine 
• 1376514-48-5 N₄-[(3S)-1-(benzyloxy)hexan-3-yl]-5-{4-[3-(dimethylamino)propoxy]-2-methoxybenzyl}-6-methylpyrimidine-2,4-diamine 
• 1376514-10-1 2-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-5-[3-(dimethylamino)propoxy]phenol 

Relevant academic research and scientific papers

CARBOXYLIC ACID COMPOUNDS

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

PHENOL COMPOUNDS ALS TOLL -LIKE RECEPTOR 7 AGONISTS

The invention concerns compounds of Formula (I): wherein R1, R2, R3 and Q are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful

AMINOALKOXYPHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE

The invention concerns compounds of Formula (I): (I) wherein n, m, p, R1 and R2 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful in the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES

The invention concerns compounds of Formula (I): wherein L1, R1, R2, R3, R4 and X are as defined in the description. The present invention also relates to processes for the preparation of such compoun